BRPI0408529A - derivados 6-sulfonamida de quinolina e cromeno como antagonistas dos receptores de androgênios - Google Patents

derivados 6-sulfonamida de quinolina e cromeno como antagonistas dos receptores de androgênios

Info

Publication number
BRPI0408529A
BRPI0408529A BRPI0408529-9A BRPI0408529A BRPI0408529A BR PI0408529 A BRPI0408529 A BR PI0408529A BR PI0408529 A BRPI0408529 A BR PI0408529A BR PI0408529 A BRPI0408529 A BR PI0408529A
Authority
BR
Brazil
Prior art keywords
quinoline
chromene
receptor antagonists
androgen receptor
sulfonamide derivatives
Prior art date
Application number
BRPI0408529-9A
Other languages
English (en)
Inventor
Daniel Yunlong Du
Martin James Procter
Matthew Colin Thor Fyfe
Vilasben Kanji Shah
Geoffrey Martyn Williams
Karen Lesley Schofield
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BRPI0408529A publication Critical patent/BRPI0408529A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/14—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 6 and unsubstituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"DERIVADOS 6-SULFONAMIDA DE QUINOLINA E CROMENO COMO ANTAGONISTAS DOS RECEPTORES DE ANDROGêNIOS". A presente invenção refere-se a derivados de quinolina e cromeno 6-sulfonamida de fórmula (I) com as definições de M, R¬ 1¬, R¬ 2¬, A e B de acordo com a reivindicação 1 e a sua utilização como antagonistas dos receptores de androgênios.
BRPI0408529-9A 2003-03-20 2004-03-17 derivados 6-sulfonamida de quinolina e cromeno como antagonistas dos receptores de androgênios BRPI0408529A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45631603P 2003-03-20 2003-03-20
PCT/IB2004/000856 WO2004083204A1 (en) 2003-03-20 2004-03-17 6-sulfonamide quinoline and chromene derivative as androgen receptor antagonists

Publications (1)

Publication Number Publication Date
BRPI0408529A true BRPI0408529A (pt) 2006-03-07

Family

ID=33030093

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408529-9A BRPI0408529A (pt) 2003-03-20 2004-03-17 derivados 6-sulfonamida de quinolina e cromeno como antagonistas dos receptores de androgênios

Country Status (7)

Country Link
US (1) US7009052B2 (pt)
EP (1) EP1608643A1 (pt)
JP (1) JP2006520780A (pt)
BR (1) BRPI0408529A (pt)
CA (1) CA2517446A1 (pt)
MX (1) MXPA05009988A (pt)
WO (1) WO2004083204A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2874922A1 (fr) * 2004-07-30 2006-03-10 Palumed Sa Molecules hybrides qa ou q est une aminoquinoleine et a est un residu antibiotique, leur synthese et leurs utilisations en tant qu'agent antibacterien
AU2005279050A1 (en) * 2004-07-30 2006-03-09 Centre National De La Recherche Scientifique (Cnrs) Hybrid molecules QA where Q is an aminoquinoline and A is an antibiotic residue, and the synthesis and uses thereof as antibacterial agents
JP2008540661A (ja) * 2005-05-16 2008-11-20 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネルのモジュレーターとしての二環式の誘導体
WO2007137116A2 (en) * 2006-05-18 2007-11-29 Dow Global Technologies Inc. Polyurethane-urea polymers derived from cyclohexane dimethanol
JP5492787B2 (ja) * 2007-12-26 2014-05-14 ダウ グローバル テクノロジーズ エルエルシー ポリウレタン分散物及びこのポリウレタン分散物から製造されるコーティング
US9212182B2 (en) 2013-06-12 2015-12-15 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
JP2017505612A (ja) * 2014-01-17 2017-02-23 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ メタロ−β−ラクタマーゼを発現する細菌を検出するための６，７−トランスセファロスポリンに基づくプローブ
US20170291875A1 (en) * 2014-09-01 2017-10-12 Ucl Business Plc Quinolones as inhibitors of class iv bromodomain proteins
MA41140A (fr) * 2014-12-12 2017-10-17 Cancer Research Tech Ltd Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
MA41179A (fr) 2014-12-19 2017-10-24 Cancer Research Tech Ltd Composés inhibiteurs de parg
CN109793737B (zh) * 2017-03-01 2021-06-29 浙江大学 苯磺酰胺结构类型雄激素受体拮抗剂及其应用
WO2023067192A1 (en) * 2021-10-21 2023-04-27 Consejo Superior De Investigaciones Cientificas (Csic) Methods for improving abiotic stress resistance

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07508034A (ja) 1992-05-20 1995-09-07 メルク　エンド　カンパニー　インコーポレーテッド １７−アミノ置換４−アザステロイド５α−レダクターゼ阻害剤
FR2706454B1 (fr) * 1993-06-17 1995-09-15 Roussel Uclaf Nouveaux 19-Nor stéroïdes, procédé et intermédiaires de préparation, application comme médicaments et compositions pharmaceutiques les contenant.
US6017924A (en) * 1996-06-27 2000-01-25 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
AU778655B2 (en) 1999-08-27 2004-12-16 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
US6667313B1 (en) 1999-08-27 2003-12-23 Ligand Pharmaceuticals Inc. 8-substituted-6-triflouromethyl-9-pyrido [3,2-G] quinoline compounds as androgen receptor modulators
GB0013060D0 (en) * 2000-05-31 2000-07-19 Astrazeneca Ab Chemical compounds
DE10034801A1 (de) * 2000-07-18 2002-01-31 Bayer Ag Substituierte Amidoalkyl-uracile und ihre Verwendung
WO2002092227A1 (en) 2001-05-17 2002-11-21 Conocophillips Company Pressure swing catalyst regeneration procedure for fischer-tropsch catalyst

Also Published As

Publication number Publication date
MXPA05009988A (es) 2005-11-04
US20050004367A1 (en) 2005-01-06
EP1608643A1 (en) 2005-12-28
CA2517446A1 (en) 2004-09-30
JP2006520780A (ja) 2006-09-14
US7009052B2 (en) 2006-03-07
WO2004083204A1 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
ATE496051T1 (de) Pyrazolotetrahydropyridinderivate als orexinrezeptorantagonisten
ATE286897T1 (de) Morpholinderivate als antagonisten an orexinrezeptoren
BRPI0507462A (pt) compostos de quinolina substituìdos
DE60309481D1 (de) Cyclische n-aroylamine als orexinrezeptorantagonisten
BRPI0507574A (pt) piridazinonas como antagonistas de alfa 4 integrinas
CR10303A (es) "derivados de quinolina y su uso com pesticidas"
BRPI0409164A (pt) pirazóis substituìdos
BRPI0506477A (pt) compostos farmaceuticamente úteis e inovadores
DE122012000018I1 (de) Benzimidazolderivate und ihre verwendung als antagonisten des a II rezeptors.
BRPI0417571A (pt) 2-quinolinonas e 2-quinoxalinonas substituìdas por 6-ciclohexil-alquila substituìda como inibidores da poli(adp-ribose) polimerase
BRPI0715579A2 (pt) "composto, composição farmacêutica e uso de um composto"
WO2008038251A3 (en) 3-aza-bicyclo[3.1.0]hexane derivatives
BRPI0408529A (pt) derivados 6-sulfonamida de quinolina e cromeno como antagonistas dos receptores de androgênios
ATE349434T1 (de) Lactamderivaten zur verwendung als humane 11cby rezeptorantagonisten
ATE484505T1 (de) 5-sulfanylmethylä1,2,4ütriazolä1,5-aüpyrimidin- - olderivate als cxcr2-antagonisten
ATE467413T1 (de) Oxindolderivate als antikrebsmittel
CR8530A (es) Intermediarios de quinolona como inhibidores de receptores de tirosina quinasas y la sintesis de los mismos
DE60228487D1 (de) Ethylenediaminderivate und ihre verwendung als orexinrezeptorantagonisten
BRPI0414592A (pt) antagonistas de receptores de trombina
EA200300829A1 (ru) Производные 1-арил- или 1-алкилсульфонилбензазола в качестве лигандов 5-гидрокситриптамина-6
DE602006004997D1 (de) Indol-3-carbonyl-spiro-piperidinderivate als antagonisten des v1a-rezeptors
EA200700365A1 (ru) Производные индол-2-карбоксамидина как антагонисты nmda рецептора
ATE496916T1 (de) Chiniclidinderivate von (hetero)arylcycloheptancarbonsäuren als antagonisten am muskarinrezeptor
BR0213464A (pt) Derivados de 3-azabiciclo[3.1.0]hexano como antagonistas receptores de opióide
PT1355639E (pt) Derivados de carboestirilo substituidos como agonistas do subtipo de receptores 5-ht1a

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.